Premium
Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet‐derived growth factor in ovarian clear cell carcinoma ES‐2 cells
Author(s) -
Yasukagawa Tamami,
Niwa Yuki,
Simizu Siro,
Umezawa Kazuo
Publication year - 2012
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2012.04.007
Subject(s) - secretion , cancer research , ovarian cancer , potassium channel , cell growth , cell culture , platelet derived growth factor receptor , cell , growth factor , gene knockdown , ovarian carcinoma , chemistry , microbiology and biotechnology , biology , pharmacology , medicine , endocrinology , cancer , receptor , biochemistry , genetics
It has been demonstrated that potassium channels (K + channels) play significant roles in some malignant phenotypes. Here, we provide the first evidence that treatment with glybenclamide, an ATP‐sensitive K + channel blocker, inhibited cell migration in an ovarian clear cell carcinoma cell line, ES‐2. Treatment with glybenclamide or knockdown by siRNA targeted against K + channel subunits demonstrated the suppression of ovarian cancer cell invasion, which occurred via inhibition of PDGF‐AA secretion. Therefore, our findings suggest that K + channel blockers may be useful chemotherapeutic drugs for blocking the invasiveness of ovarian cancers.